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Abstract
The aim of our study was to determine the base levels of Growth Differentiation Factor 15, P-selectin and Galectin-3 in 
blood plasma in patients with AH and T2DM and to assess their association with the diseases clinical course.
Materials and methods. A total of 121 patients were included in our study (60 female and 61 male, mean age 64.7± 
±10.6 years, with AH and/or T2DM).
Patients were divided into three groups: 1st group with AH only (51 patient), 2nd group with AH and T2DM (57 patients) 
and 3rd group with T2DM only (13 patients, control group). GDF-15, Galectin-3 and P-selectin tests were performed using stan-
dard enzyme-linked immunosorbent assay kits (ELISA).
Results. Compared with AH without T2DM and T2DM only groups, AH with T2DM group had a statistically significant 
higher level of GDF-15. Grade 3 hypertension group had a significantly lower level of GDF-15 compared with Grade 1&2 hyper-
tension groups. P-selectin mean level was significantly higher in Grade 3 hypertension group GDF-15 compared with Grade 1&2 
hypertension groups. We observed weak correlation between Galectin-3 and GDF-15 in blood plasma, which was confirmed by 
linear regression analysis. 
Conclusions. A combination of hypertension and type 2 diabetes mellitus revealed a significant increase of GDF-15 levels 
in compare with patients with only hypertension or type 2 diabetes mellitus, which may be due to a greater response to oxidative 
stress and low-intensity systemic inflammation.
P-selectin mean level was higher in patients with grade 3 hypertension, which reflects a greater platelet activation as a part 
of the systemic inflammatory response.
Galectin-3 mean level was higher in patients with stage 3 hypertension compared with patients with stages 1 and 2 due to 
possibly more pronounced fibrosis progression.
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1. Introduction
For decades, one of the most popular research fields in medicine is the impact of low-grade 
systemic inflammation in patients with arterial hypertension and type 2 diabetes mellitus, which 
leads to atherosclerosis and atherothrombosis. One of the major topics to be investigated in this 
field is finding the novel inflammatory markers, which will have greater prognostic significance in 
cardiovascular events and evaluation of treatment effectiveness. 
The most common systemic inflammation markers in modern risk stratification practice 
are High-sensitivity C-reactive Protein (hs-CRP), Lipoprotein-associated phospholipase A2 (Lp-
PLA2) and Myeloperoxidase (MPO) [1, 2]. Today, one of the most perspective markers are Growth 
Differentiation Factor 15 (GDF-15) [3, 4], P-selectin [5] and Galectin-3 [6, 7]. 
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Despite of increasing numbers of studies of GDF-15, P-selectin and Galectin-3 in patients 
with acute coronary syndrome, there is still need to conduct researches in patients with AH and 
T2DM, which have high additional risk of cardiovascular events. 
The aim of our study was to determine the base levels of GDF-15, P-selectin and Galectin-3 
in blood plasma in patients with AH and T2DM and to assess their association with the diseases 
clinical course.
2. Materials and methods
A total of 121 patients who visited L. T. Malaya Therapy National Institute of the National 
Academy of Medical Sciences of Ukraine (Kharkiv, Ukraine) and 26-th City Outpatient Clinic 
(Kharkiv, Ukraine) from September 2017 to December 2019 were included in our study (60 female 
and 61 male, mean age 64.7±10.6 years, with AH and/or T2DM). The study protocol was approved 
by the local Ethics Committee (The Committee on Ethics and Bioethics of Kharkiv National Med-
ical University, protocol №5 of 12 September 2017). AH was diagnosed according to ESC recom-
mendations [8], T2DM was diagnosed according to ADA recommendations [9].
Patients were divided into three groups: 1st group with AH only (51 patient, mean age – 
64.82±10.17), 2nd group with AH and T2DM (57 patients, mean age -64.71±11.51) and 3rd group with 
T2DM only (13 patients, mean age – 63.77±9.63; control group). 
OBPM and ABPM carried out according to guidelines [8, 10].
GDF-15 test was performed using standard enzyme-linked immunosorbent assay kit (ELI-
SA). The detection limitation was 16 pg/mL and a linear range from 35–4480 pg/mL (Human GDF-
15/MIC-1 Elisa, BioVendor, Czech Republic). 
P-selectin test was performed using standard enzyme-linked immunosorbent assay kit 
(ELISA). The detection limitation was 0.20 ng/mL and a linear range from 0.8–267 ng/mL (Hu- 
man sP-selectin Platinum ELISA, eBioscience, Bender MedSystems, Austria). 
Galectin-3 test was performed using standard enzyme-linked immunosorbent assay kit 
(ELISA). The detection limitation was 0.29 ng/mL and a linear range from 0.47-30.0 ng/mL (Hu-
man Galectin-3 Platinum Elisa, eBioscience, Bender MedSystems, Austria). 
Statistics were calculated using IBM SPSS (V 25, USA). Data are presented as mean val-
ue with standard deviation (mean±SD). Student’s t-test, Mann-Whitney U test, Pearson or Spear-
man analysis, linear regression analysis and analysis of variance (ANOVA) were used to compare 
groups, dependent on the type and distribution of the data. 
3. Results
Mean GDF-15 in blood plasma in all groups was 2944.59±2004.66 pg/mL, Galectin-3 – 
12.65±5.35 ng /mL, P-selectin – 110.14±37.08 ng /mL, hs-CRP – 6.53±4.259 mg/L. 
Compared with AH without T2DM and T2DM only groups, AH with T2DM group had 
a higher level of GDF-15 (3824.71±2474.41; 2130.48±874.52; 3039.04±1440.89 ng/mL, р<0.05) 
(Table 1). AH without T2DM group had a higher mean P-selectin level than T2DM only group, but 
this difference did not reach confidence level.
Table 1
Mean inflammatory marker levels by group
Group
Inflammatory markers
GDF-15 (pg/mL) P-selectin (ng/mL) Galectin-3 (ng/mL) hs-CRP (mg/L)
1st group AH and T2DM (n=51) 3824.71±2474.41* 114.09±36.06 12.47±4.65 4.85±3.46
2nd group AH only (n=57) 2130.48±874.52 106.61±37.93 12.83±5.95 5.92±4.44
3rd group T2DM only (n=13) 3039.04±1440.89 109.85±61.89 14.50±9.67 5.59±4.80
Note: * – р<0.05 in comparison with other groups 
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Gal-3 mean level was higher in T2DM only group compared to others, but statistical sig-
nificance was not met (12.47±4.65; 12.83±5.95 and 14.50±9.67 ng/mL, р>0.05). Mean hs-CRP lev-
el was insignificantly higher in AH and T2DM group compared to AH only group (4.85±3.46; 
5.92±4.44 mg/L, р>0.05).
In order to confirm significant difference between groups we performed ANOVA test 
(Table 2). GDF-15 had a significant difference between different groups. There were no statistical-
ly significant differences of other marker levels between groups.
Table 2
ANOVA test between different groups
Groups Sum of Squares df Mean Square F Sig.
Galectin-3
Between Groups 42.972 2 21.486 0.606 0.547
Within Groups 4185.592 118 35.471
Total 4228.564 120
P-selectin
Between Groups 1506.830 2 753.415 0.464 0.630
Within Groups 191571.438 118 1623.487
Total 193078.268 120
GDF-15
Between Groups 37140951.671 2 18570475.836 10.422 0.000
Within Groups 138985104.188 78 1781860.310
Total 176126055.859 80
hs-CRP
Between Groups 78.527 2 39.264 2.234 0.122
Within Groups 632.739 36 17.576
Total 711.267 38
We analysed inflammatory marker levels according to hypertension grade classification [8] 
(Table 3).
Table 3
Mean inflammatory marker levels by hypertension grade
Blood pressure
Inflammatory markers
GDF-15 (pg/mL) P-selectin (ng/mL) Galectin-3 (ng/mL) hs-CRP (mg/L)
Normal BP (n=31) 1892.06±788.23 100.50±42.73 13.44±6.50 5.43±4.48
High normal BP (n=25) 2346.26±1274.45 111.64±35.71 14.27±7.19 9.41±4.24
Grade 1 hypertension (n=31) 2942.03±1367.95 111.50±45.81 12.28±4.88 6.86±3.95
Grade 2 hypertension (n=26) 3303.33±1811.94 111.10±35.60 11.88±5.39 4.85±3.20
Grade 3 hypertension (n=8) 3542.43±3068.59*† 133.95±28.13* 11.58±4.95 4.81±4.10
Note: * – р<0.05 in comparison with Normal BP; † – р <0.05 in compassion with Grade 1 hypertension group
Grade 3 hypertension group had a significantly higher level of GDF-15 compared with 
Grade 1&2 hypertension groups. P-selectin mean level was significantly higher in Grade 3 hyper-
tension group GDF-15 compared with Grade 1&2 hypertension groups. There were no statistically 
significant differences in Galectin-3 levels between groups.
We analysed inflammatory marker levels according to hypertension stages classifica-
tion [8] (Table 4).
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Mean inflammatory marker levels by hypertension stage
Hypertension disease  
staging
Inflammatory markers
GDF-15 (pg/mL) P-selectin (ng/mL) Galectin-3 (ng/mL) hs-CRP (mg/L)
Stage 1 (n=4) 3278.45 97.71±30.69 11.25±3.40 8.91±4.38
Stage 2 (n=18) 2096.23±1613.24 123.59±51.82 9.85±3.86 6.98±2.73
Stage 3 (n=86) 3083.02±2054.41 107.91±33.31 13.31±5.52* 6.05±4.68
Note: * – р<0.05 in comparison with other groups 
We observed no significant difference of GDF-15 and P-selectin levels between dif-
ferent stage groups. Stage 3 hypertension group had a significantly lower level of Galectin-3 
compared with Stage 1&2 hypertension groups (13.31±5.52; 11.25±3.40 and 9.85±3.86 ng/mL, 
р<0.05). 
In order to confirm significant difference between different stages we performed ANOVA 
test (Table 5).
Table 5
ANOVA test between different hypertension stages
Groups Sum of Squares df Mean Square F Sig.
Galectin-3
Between groups 186.401 2 93.201 3.398 0.037
Within groups 2879.791 105 27.427
Total 3066.193 107
P-selectin
Between groups 4300.701 2 2150.350 1.581 0.211
Within groups 142809.566 105 1360.091
Total 147110.267 107
GDF-15
Between groups 9273904.055 2 4636952.028 1.159 0.320
Within groups 296143273.551 74 4001936.129
Total 305417177.607 76
hs-CRP
Between groups 23.337 2 11.668 0.627 0.541
Within groups 520.873 28 18.603
Total 544.210 30
According to ANOVA test, Galectin-3 had a significant difference between different hy-
pertension stages (F=3.398; p=0.037). There were no statistically significant differences of other 
marker levels between groups.
We performed correlation and regression analysis due to different pathogenetic mechanisms 
of inflammatory markers. There were no significant correlations between P-selectin and GDF-15 
(r=–0.114 p=0.323), Galectin-3 and hs-CRP (r=0.199, p=0.142) and P-selectin and hs-CRP (r=0.133, 
p=0.476).We observed weak correlation between Galectin-3 and GDF-15 in blood plasma (r=0.260 
p=0.022), which was confirmed by linear regression analysis (Fig. 1).
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Fig. 1. Linear regression between Galectin-3 and GDF-15 plasma levels
4. Discussion 
Correlation and regression analysis between inflammatory markers showed a weak rela-
tionship between galectin-3 and RDF-15 levels in the plasma and no significant correlations with 
P-selectin and standard systemic inflammation marker hs-CRP. We consider that our results create 
the prerequisites for searching an additional diagnostic and prognostic information. 
In general, GDF-15 levels were significantly higher in patients with group of patients with 
hypertension and type 2 diabetes. Other studies have shown that GDF-15 activates atherosclerotic 
injury through interleukin-6 (IL-6) pro-inflammatory mechanisms [11, 12].
For increasing GDF-15 levels, it is necessary to activate a promoter with 2 p53 transcrip-
tion factor binding sites, which is the fundamental response of cells to inflammation, oxidative 
stress, and oncogenic activation [13, 14]. It is interesting to note that we detected maximum ex-
pression of GDF-15 in patients with hypertension and type 2 diabetes due to, probably, a greater 
damage to cells, which is associated with oxidative stress and low-intensity systemic inflamma-
tion. We also revealed a significant increase of P-selectin levels in patients with grade 3 hyper-
tension. It is known that P-selectin, which is released on activated platelets and endothelial cells, 
can act as a counter ligand for GPIbα and, therefore, may mediate platelet adhesion and thrombus 
formation [15, 16]. We suggest that the increase of P-selectin level reflects the activation of the 
platelet link of systemic inflammation in patients with grade 3 hypertension. 
An increase of Galectin-3 level is primarily associated with the fibrosis progression as well 
as the development of heart failure [17, 18] and diabetes mellitus [19, 20]. The revealed increase in 
Galectin-3 in patients with stage 3 hypertension may be associated with the development of fibrosis 
and the initial stages of heart failure.
Study limitations. First, while the total sample size in our study was relatively large, the 
sample size of patients only with T2DM was small due to low frequency of patients without AH 
in this age. 
Second, some plasma samples were stored more than 6 months.
On this basis, we conclude that the new inflammatory markers GDF-15, P-selectin and 
Galectin-3 reflect different pathogenetic mechanisms activation which are responsible for low-in-
tensity systemic inflammation in patients with hypertension and type 2 diabetes and may provide 
various new diagnostic and prognostic information. 









1. A combination of hypertension and type 2 diabetes mellitus revealed a significant in-
crease of GDF-15 levels in compare with patients with only hypertension or type 2 diabetes melli-
tus (3824.71±2474.41; 2130.48±874.52 and 3039.04±1440.89 pg/mL; р<0.05), which may be due to 
a greater response to oxidative stress and low-intensity systemic inflammation.
2. P-selectin mean level was higher in patients with grade 3 hypertension (grade 3 – 
133.95±28.13 Normal BP – 100.50±42.73 ng/mL; р<0.05), which reflects a greater platelet activa-
tion as a part of the systemic inflammatory response.
3. Galectin-3 mean level was higher in patients with stage 3 hypertension compared with 
patients with stages 1 and 2 (13.31±5.52; 11.25±3.40 and 9.85±3.86 ng/mL; р<0.05) due to possibly 
more pronounced fibrosis progression.
4. A weak correlation between GDF-15 and Galectin-3 was revealed (r=0.260, p=0.022). 
There was no significant correlation between P-selectin and Galectin-3 as with the standard mark-
er of inflammation hs-CRP which reflect the activation of various pathogenetic mechanisms of 
low-intensity systemic inflammation in patients with hypertension and type 2 diabetes. Therefore, 
this information creates the prerequisites for individualizing therapeutic goals.
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Abstract
The aim of the study. Due to the growing prevalence of food hypersensitivity worldwide and the number of dangerous 
food reactions, the aim was to determine the current prevalence of food hypersensitivity symptoms among children in the Kyiv 
region, Ukraine.
Methods. Total of 7106 children were surveyed: Group I (4 months – 5 years) had 1787 children, Group II (6–7 years) – 
2080 children, Group ІІI (13–14 years) – 1909 children, Group ІV (15–17 years) – 1330 children.
Results. The prevalence of food hypersensitivity among the surveyed children is 26.5 % (95 % CI: 25.5–27.6) – this is 
1888 children out of 7106. Highest prevalence of food hypersensitivity (FHS) is observed in the Group I, which is 32 % (95 % CI: 
29.8–34.2) – 571/1787, Groups II – 27.2 % (95 % CI: 25.7–29.8) – 566/2080, Groups III – 27.7 % (95 % CI: 14.7–18.0) – 529/1909, in 
the Group IV – 16.7 % (95 % CI: 25.3-29.2) – 222/1330). FHS in children is most often manifested by skin symptoms, followed by 
gastrointestinal manifestations, and acute urticaria/angioneurotic edema is at the third place. Respiratory manifestations possess 
5 % in the structure of FHS symptoms. An anaphylactic reaction was observed in 4 children out of 7106 respondents.
Conclusions. The prevalence of food hypersensitivity among Ukrainian children is high. There is an increase in the prev-
alence of urticaria/angioedema in preschool children.
Keywords: epidemiology, the prevalence of food hypersensitivity, food allergy, children, urticaria.
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